Stay updated on AK104 Plus Anlotinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the AK104 Plus Anlotinib in NSCLC Clinical Trial page.

Latest updates to the AK104 Plus Anlotinib in NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange Detected- Replaced version tag from v3.1.0 to v3.2.0 and added a prominent notice about government funding impact and operating status with references to NIH Clinical Center and official sources.SummaryDifference13%

- Check28 days agoChange DetectedUpdated the site/page version from v3.0.2 to v3.1.0, indicating a newer release. No other substantive content changes detected.SummaryDifference0.3%

- Check43 days agoChange DetectedThe page revision was bumped from v3.0.1 to v3.0.2, and the 'Back to Top' link was removed.SummaryDifference0.8%

- Check50 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.8%

- Check57 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information.SummaryDifference10%

- Check64 days agoChange DetectedThe page has been updated to reflect a new completion status and a future date of August 19, 2025, while removing a previous status indicating that it was not actively recruiting and a date of March 3, 2025.SummaryDifference1%

Stay in the know with updates to AK104 Plus Anlotinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AK104 Plus Anlotinib in NSCLC Clinical Trial page.